09:48 AM EST - ProMIS Neurosciences, Inc. : Announced today that, in addition to its ongoing program to develop a high-throughput and accurate test for detection of antibodies to the causative agent of COVID-19, it has expanded its collaboration with BC Neuroimmunology to include development of highly sensitive and specific assays to support accurate screening and diagnosis of Alzheimer’s disease. ProMIS Neurosciences, Inc.
shares T.PMN are trading unchanged at $0.15.